IGC Pharma, Inc.

Healthcare · Biotechnology · United States

Last price 0.185 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 19.13M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi...